



## **ZAI Lab secures over \$30M in Series A financing commitment from leading healthcare investors**

Shanghai, 27 August 2014 – ZAI Lab, an innovative drug development and commercialization company, announced today the completion of its Series A financing from a leading group of healthcare investors. The investment was led by Qiming Venture Partners and included KPCB, Sequoia Capital and TF Capital.

The funding will be used to support ZAI Lab's clinical development programs as well as the company's ongoing in-licensing efforts. ZAI Lab is building a world class organization of global experts to focus on developing novel medicines in the therapeutic areas of oncology, autoimmune and anti-infective.

Commenting on the financing, Dr. Samantha Du, founder and CEO said: "We are gratified to have received such strong financial support from this exceptional group of investors. This financing will take the company into an exciting growth phase and we believe that ZAI's future products will benefit millions of patients worldwide."

Nisa Leung, managing partner of Qiming Ventures, said: "Zai Lab is the leading innovative drug development company in China today. Led by Dr. Samantha Du, Zai has an experienced management team with strong track record in China and globally. I have known this team for many years and they have unwavering support from the investment syndicate to build a global biotech powerhouse based in China"

### **About ZAI Lab**

ZAI Lab is a biotech company based in Shanghai focused on developing innovative medicines for unmet medical needs. The company is building a strong portfolio of therapeutic programs aimed at transforming patients' lives, specifically targeting not only Asian but also global patients. Zai Lab has an experienced founding and leadership team with deep experience at global pharmaceutical and biotech organizations. The team has a strong track record of success – involved with the launch of over half of a dozen drugs globally and successfully taken five novel drug candidates into clinical trials in China, pioneered new regulatory channels, secured regulatory approvals in record times, conducted multiple IND trials in the US, and brought the first China discovered drug into Global Phase III trials. Zai Lab is committed to build a globally leading drug development powerhouse with a culture of excellence and teamwork, and a strong focus on fostering innovation and creativity.

For more information, please visit [www.zailaboratory.com](http://www.zailaboratory.com)

### **About Qiming Venture Partners**

Qiming Venture Partners is a leading venture capital firm in China with offices in Shanghai, Beijing, Hong Kong, Suzhou and Seattle. Founded in February 2006, Qiming currently manages six funds with \$1.6 Billion in assets and focuses on early to growth stage investments in Internet and Consumer (Intersumer), Healthcare, Information Technology, and Cleantech industries. Qiming's 30 partners and investment professionals who all have strong operational experience and successful investment track records add a great deal of value to the portfolio companies. Qiming has invested in over 100 companies and many of them have gone IPO or mergers and acquisitions. Qiming has established a great reputation and strives to be the top investment partner by the Chinese entrepreneurs.

For media enquiries, please contact:

ZAI Lab

Jonathan Wang, +86 21 6163 2587

[bd@zailaboratory.com](mailto:bd@zailaboratory.com)